Analysis updated on Nov. 10, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Our AI scores Takeda Pharmaceutical Co Ltd every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Takeda Pharmaceutical Co Ltd is a large-cap company with a market capitalization of $65.88B. It ranks number 15 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For TAK, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 358 forecast dates between 2022-08-23 and 2026-08-12 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -16.0%, measured on 400 forecast dates between 2022-08-23 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.6%, sell < -0.3%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-09 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, TAK included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric. Statement values were filed in JPY and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
| Metric | TAK | Rank |
|---|---|---|
| Market Cap | $65.88B | 15/60 |
| P/E Ratio | 6.35x | 28/32 |
| EPS | $3.32 | – |
| Revenue/Share | $34.55 | – |
| FCF/Share | $6.79 | – |
| Metric | TAK | Rank |
|---|---|---|
| Gross Margin | 67.4% | 29/36 |
| Operating Margin | 9.2% | 20/38 |
| Net Margin | 4.9% | 19/35 |
| EBT Margin | 5.5% | 26/46 |
| Tax Rate | 11.7% | – |
| Metric | TAK | Rank |
|---|---|---|
| Operating Cash Flow | $25.43B | 8/59 |
| Free Cash Flow | $21.23B | 5/50 |
| Capital Spending | -$4.20B | 46/50 |
| FCF Growth YoY | 0.0% | 15/32 |
| FCF/Sales | 19.7% | 18/42 |
| CapEx/Sales | 3.9% | 17/42 |
| Metric | TAK | Rank |
|---|---|---|
| Total Revenue | $107.93B | 4/46 |
| Operating Income | $9.90B | 7/50 |
| Net Income | $5.25B | 9/47 |
| R&D Expense | $17.20B | 7/58 |
| Cost of Goods Sold | $35.17B | 3/37 |
| Metric | TAK | Rank |
|---|---|---|
| Shares Outstanding | 3124M | – |
| Total Liabilities | $48.76B |
Companies classified under the same SEC industry code as Takeda Pharmaceutical Co Ltd (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| TAK Takeda Pharmaceutical Co Ltd | $65.88B | |
| LLY Eli Lilly & Co | $1.33T | |
| JNJ Johnson & Johnson | $679.13B | |
| ABBV Abbvie Inc. | $518.30B | |
| MRK Merck & Co., Inc. | $367.02B | |
| NVS Novartis Ag | $312.35B | |
| AZN Astrazeneca Plc | $293.55B | |
| ABT Abbott Laboratories | $192.16B | |
| NVO Novo Nordisk A S | $183.89B | |
| PFE Pfizer Inc | $166.60B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $139.62B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $118.63B | |
| GSK Gsk Plc | $103.98B | |
| REGN Regeneron Pharmaceuticals, Inc. | $94.71B | |
| TEVA Teva Pharmaceutical Industries Ltd | $50.07B | |
| ONC Beone Medicines Ltd. | $47.44B | |
| GMAB Genmab A/S | $35.90B | |
| ZTS Zoetis Inc. | $32.81B | |
| RPRX Royalty Pharma Plc | $29.45B | |
| ROIV Roivant Sciences Ltd. | $29.38B | |
| INSM Insmed Inc | $25.47B | |
| UTHR United Therapeutics Corp | $24.98B | |
| VTRS Viatris Inc | $23.53B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | |
| ASND Ascendis Pharma A/S | $17.07B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.81B | |
| BBIO Bridgebio Pharma, Inc. | $15.18B | |
| SMMT Summit Therapeutics Inc. | $14.23B | |
| ELAN Elanco Animal Health Inc | $13.41B | |
| RDY Dr Reddys Laboratories Ltd | $12.56B | |
| BMRN Biomarin Pharmaceutical Inc | $11.07B | |
| TGTX Tg Therapeutics, Inc. | $10.06B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $10.00B | |
| SYRE Spyre Therapeutics, Inc. | $9.61B | |
| PRAX Praxis Precision Medicines, Inc. | $9.30B | |
| PTGX Protagonist Therapeutics, Inc | $8.79B | |
| CORT Corcept Therapeutics Inc | $8.11B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.85B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.76B | |
| ALKS Alkermes Plc. | $7.75B | |
| CYTK Cytokinetics Inc | $7.67B | |
| AXSM Axsome Therapeutics, Inc. | $7.02B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.96B | |
| ORKA Oruka Therapeutics, Inc. | $6.92B | |
| ABVX Abivax S.A. | $6.83B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.80B | |
| LGND Ligand Pharmaceuticals Inc | $6.28B | |
| BLTE Belite Bio, Inc | $6.20B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.05B | |
| MANE Veradermics, Inc | $6.01B | |
| COGT Cogent Biosciences, Inc. | $5.82B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| ERAS Erasca, Inc. | $5.46B | |
| PTCT Ptc Therapeutics, Inc. | $5.43B | |
| EWTX Edgewise Therapeutics, Inc. | $5.29B | |
| IONS Ionis Pharmaceuticals Inc | $5.15B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $5.03B | |
| TVTX Travere Therapeutics, Inc. | $4.62B | |
| LEGN Legend Biotech Corp | $4.49B |
This article first appeared on GuruFocus. Takeda Pharmaceutical Co Ltd (TSE:4502) is set to release its Q2 2025 earnings on Oct 30, 2025. The consensus estimate for Q2 2025 revenue is $1.17 billion, ...
Takeda Pharmaceutical Co Ltd TAK on Thursday reported second-quarter adjusted earnings of 48 cents per share, beating the ...
Takeda's pivot to rare diseases and plasma therapies tests if specialized drugs can drive steady growth amid patent cliffs. For investors in the United States and English-speaking markets worldwide, ...
Our AI scores Takeda Pharmaceutical Co Ltd every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For TAK, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -14.0%, measured on 358 forecast dates between 2022-08-23 and 2026-08-12 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -16.0%, measured on 400 forecast dates between 2022-08-23 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Takeda Pharmaceutical Co Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 10, 2026.
60 issuers in our coverage, TAK included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
